Vimovo (naproxen/esomeprazole magnesium) 

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) May 2016 New safety information pertaining to the risks of Cardiovascular Thrombotic Events, Heart Failure and Edema. In addition, some...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts